2009
NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer.
Burtness B, Anadkat M, Basti S, Hughes M, Lacouture ME, McClure JS, Myskowski PL, Paul J, Perlis CS, Saltz L, Spencer S. NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. Journal Of The National Comprehensive Cancer Network 2009, 7 Suppl 1: s5-21; quiz s22-4. PMID: 19470276, DOI: 10.6004/jnccn.2009.0074.Peer-Reviewed Original ResearchConceptsTask force membersEGFR inhibitorsEpidermal growth factor receptor inhibitorsGrowth factor receptor inhibitorsNCCN Member InstitutionsOphthalmologic toxicityOncology providersOcular toxicityClinical trialsDifferent etiologiesReceptor inhibitorsEGFR inhibitionPatientsTask Force ReportTherapyToxicityInhibitorsSimilar toxicityTask ForceForce ReportReportExpert opinionOncologistsEtiologyOphthalmologists
2008
Oropharyngeal cancer.
Psyrri A, Prezas L, Burtness B. Oropharyngeal cancer. Clinical Advances In Hematology And Oncology 2008, 6: 604-12. PMID: 18820604.Peer-Reviewed Original ResearchConceptsOropharyngeal squamous cell carcinomaMolecular pathogenesisHigh-risk human papillomavirus (HPV) typesSquamous cell carcinomaHuman papillomavirus typesTerms of etiologySquamous histologyClinical presentationCell carcinomaClinical behaviorPapillomavirus typesType 16Significant heterogeneityCarcinomaPathogenesisHPVOropharynxEtiologyTherapyHistologyInfectionEpidemiologyDiagnosis